Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents

Specific immunotherapy in grass pollen allergy

“…The development of sublingual tablets for pollen SIT has led to large scale clinical trials in adult 17,18 and pediatric [19][20][21] populations. These studies have confirmed the efficacy of the treatment for the first pollen season.…”

Health-Related Quality of Life and Rhinitis Control Measures in Allergic Rhinitis

“…The RQLQ has been used in many well-powered clinical trials as a secondary outcome both for subcutaneous [38,39] and sublingual immunotherapy [40][41][42][43] in adults and children [44]. These studies have shown that immunotherapy improves HRQoL in allergic rhinoconjunctivitis patients.…”

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

“…The standardised sublingual grass allergy immunotherapy tablet (SQ Ò grass SLIT tablet) has been developed for sublingual application in patients with grass pollen-induced rhinoconjunctivitis, and has been investigated in more than 5700 patients in controlled clinical trials in Europe and North America [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. It has been approved Europe-wide and was launched in Germany in November 2006.…”